IGC Pharma director gets 750,000 options at $0.35 exercise price

IGC Pharma (IGC) reported a director’s stock option grant on a Form 4.

Rhea-AI Filing Summary

IGC Pharma (IGC) reported a director’s stock option grant on a Form 4. The filing shows 750,000 options with a $0.35 exercise price tied to a transaction dated 10/17/2025. According to the footnote, the options vest equally over three years starting March 31, 2026, and expire on March 31, 2038. Following the grant, 750,000 derivative securities were beneficially owned, held directly.

Insider Trade Summary

Grant/Award: 750,000 shares

Grant/Award 1 txn

Insider PRINS RICHARD K

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Options	750,000	$0.00	$0.00

Holdings After Transaction: Options — 750,000 contracts (Direct)

Footnotes (1)

1. F1. The Reporting Person was granted 750,000 options exercisable at $0.35, equally vesting over the next three years starting on March 31st, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IGC (IGC) disclose in this Form 4?

A director received 750,000 stock options with a $0.35 exercise price tied to a transaction dated 10/17/2025.

How do the IGC director’s options vest and when do they expire?

They vest equally over three years starting 03/31/2026 and expire on 03/31/2038.

How many derivative securities were owned after the reported transaction?

The filing lists 750,000 derivative securities beneficially owned directly after the grant.

What is the reported exercise price for the granted options?

The exercise price is $0.35 per share.

What is the earliest transaction date in the IGC Form 4?

The earliest transaction date is 10/17/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/22/2025 - 08:29 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PRINS RICHARD K

(Last) (First) (Middle)

10224 FALLS ROAD

(Street)

POTOMAC MD 20854

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IGC Pharma, Inc. [ IGC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	(1)	10/17/2025		A		750,000(1)		(1)	03/31/2038	Common Stock	750,000	$0.0	750,000(1)	D

Explanation of Responses:

1. The Reporting Person was granted 750,000 options exercisable at $0.35, equally vesting over the next three years starting on March 31st, 2026.

	/s/ Richard Prins	10/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.